Yi-Bin Chen, MD

Articles

Novel Agents in Acute GvHD

February 3rd 2023

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Steroid Refractory Acute GvHD and REACH Trials

January 27th 2023

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options

January 27th 2023

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

Future of Acute GvHD Prevention

January 20th 2023

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Clinical Implications of the Phase III BMT CTN 1703 Trial

January 20th 2023

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

Regimens Used for GvHD Prevention

January 13th 2023

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

An Overview of Graft vs Host Disease (GvHD)

January 13th 2023

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Using Multidisciplinary Care to Optimize Outcomes in GVHD

August 29th 2022

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Treatment Advances on the Horizon for Acute GVHD

August 22nd 2022

Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.

Treatment Advances on the Horizon for Chronic GVHD

August 22nd 2022

Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.

Steroid-Refractory Chronic GVHD: Selecting and Sequencing Therapy

August 15th 2022

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Treatment Armamentarium for Steroid-Refractory Chronic GVHD

August 15th 2022

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

Frontline Treatment Strategies for Chronic GVHD

August 8th 2022

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Improving the Early Identification of Chronic Graft Versus Host Disease

August 8th 2022

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.

Identifying the Role of the Microbiome in HSCT and GVHD

August 1st 2022

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials

August 1st 2022

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease

July 25th 2022

Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.

What is the Role of Biomarker Testing in GVHD?

July 25th 2022

A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.

Challenges in Making a Diagnosis of Acute GVHD

July 18th 2022

Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.

Educating Patients and Caregivers on the Impact of Graft Versus Host Disease

July 18th 2022

Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.